Charles River Laboratories International Stock News

Charles River (CRL) delivered earnings and revenue surprises of 1.48% and 0.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MedTech companies' results are likely to reflect a rebound in the base business. Let's see how CRL, IDXX and NUVA fare this time.

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Robust global demand for the research model and multiple initiatives to expedite the discovery process are likely to have contributed to Charles River's (CRL) first-quarter results.

Explora BioLabs' business is likely to complement and expand the Charles River's (CRL) CRADL operation within the broader Insourcing Solutions business.

Investors are optimistic about Charles River's (CRL) strong segmental growth and notable partnerships.

Charles River (CRAI) has a diversified business with service offerings across areas of functional expertise, client base and geographical regions.

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

LTX, Broadridge Financial Solutions, Inc.’s artificial intelligence (AI)-driven digital trading platform, has completed a successful integration with the Charles River Investment Management Solution (Charles River IMS). The complete integration enables Charles River’s order and execution management system (OEMS) users to better access aggregated liquidity and leverage transparency and price discovery within their existing workflows through their existing […] The post Broadridge’s LTX Completes Integration with Charles River Development appeared first on AiThority .

Investors are optimistic about Charles River (CRL) on robust demand in Biologics Testing Solutions and Microbial Solutions businesses.

Charles River's (CRAI) fourth-quarter 2021 revenues improve year over year.

The acquisitions of Cognate BioServices and Vigene Biosciences contribute to the growth of Charles River's (CRL) Manufacturing Solutions arm.

Street firms are having different reactions to Charles River Laboratories'' (CRL) Q4 2021 results, in which it beat on the top and bottom lines.

Charles River Laboratories International, Inc. (CRL) CEO James Foster on Q4 2021 Results - Earnings Call Transcript